Janux Therapeutics’ (JANX) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research note released on Thursday,Benzinga reports. They currently have a $100.00 price target on the stock.

Several other equities research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a research report on Monday, August 19th. Wedbush reaffirmed an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. UBS Group began coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price on the stock. Finally, Scotiabank dropped their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.44.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded down $0.29 on Thursday, hitting $53.92. The stock had a trading volume of 844,960 shares, compared to its average volume of 713,695. The firm has a market capitalization of $2.81 billion, a P/E ratio of -46.33 and a beta of 3.52. The stock has a 50 day moving average of $48.88 and a 200 day moving average of $46.35. Janux Therapeutics has a twelve month low of $5.65 and a twelve month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. The firm’s quarterly revenue was down 82.6% compared to the same quarter last year. Equities analysts expect that Janux Therapeutics will post -1.18 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the completion of the transaction, the insider now directly owns 3,162,851 shares of the company’s stock, valued at approximately $132,839,742. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the completion of the sale, the insider now directly owns 3,162,851 shares in the company, valued at $132,839,742. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Andrew Hollman Meyer sold 50,000 shares of the business’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the transaction, the insider now owns 67,592 shares in the company, valued at approximately $3,106,528.32. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 420,610 shares of company stock valued at $19,288,666 in the last 90 days. Insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Several institutional investors have recently bought and sold shares of the business. Summit Securities Group LLC purchased a new stake in shares of Janux Therapeutics during the second quarter worth approximately $29,000. Amalgamated Bank raised its position in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd acquired a new position in Janux Therapeutics in the second quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after buying an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Janux Therapeutics during the 2nd quarter worth approximately $151,000. 75.39% of the stock is owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.